Detalhe da pesquisa
1.
Enhancing Kidney Transplantation and the Role of Xenografts: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Am J Kidney Dis
; 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452918
2.
American Society of Transplant Surgeons-American Society of Transplantation report of FDA meeting on regulatory expectations for xenotransplantation products.
Am J Transplant
; 23(9): 1290-1299, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37217005
3.
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
J Neurol Neurosurg Psychiatry
; 94(9): 757-768, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37221052
4.
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
Mult Scler
; 29(8): 945-955, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37282545
5.
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
Ann Neurol
; 89(5): 895-910, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724534
6.
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Mult Scler
; 28(6): 925-932, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595983
7.
Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
Br J Clin Pharmacol
; 88(8): 3803-3812, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332558
8.
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Mult Scler
; 27(13): 2052-2061, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538237
9.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Lancet
; 394(10206): 1352-1363, 2019 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31495497
10.
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Mult Scler
; 25(2): 235-245, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29143550
11.
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.
Mult Scler
; 22(7): 862-72, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26666258
12.
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Lancet Neurol
; 23(6): 588-602, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38760098
13.
Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis.
Clin Pharmacokinet
; 61(3): 387-400, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34718986
14.
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Mult Scler Relat Disord
; 57: 103352, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158461
15.
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Mult Scler Relat Disord
; 57: 103356, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158465
16.
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
EBioMedicine
; 86: 104321, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370634
17.
YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study.
Clin Transplant
; 25(4): 523-33, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-20573162
18.
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Neurol Neuroimmunol Neuroinflamm
; 8(3)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33771837
19.
Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience.
Mult Scler Relat Disord
; 46: 102542, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33296965
20.
Neuromyelitis optica spectrum disorder: Patient experience and quality of life.
Neurol Neuroimmunol Neuroinflamm
; 6(4): e580, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31355316